Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26053311 | 0.85 | CA1 (0.58) | ALDH1A1CA1HTTLMNAPPARA | |
| SCHEMBL6816645 | 0.78 | — | — | |
| SCHEMBL4175850 | 0.77 | ALDH1A1 (0.60) | ALDH1A1CA1HTTLMNACA2 | |
| SCHEMBL3759352 | 0.77 | ALDH1A1 (0.60) | ALDH1A1CA1HTTLMNACA2 | |
| SCHEMBL4614428 | 0.77 | ALDH1A1 (0.67) | ALDH1A1CA1HTTLMNACA2 | |
| SCHEMBL7355629 | 0.77 | ALDH1A1 (0.67) | ALDH1A1CA1HTTLMNACA2 | |
| SCHEMBL4614425 | 0.77 | ALDH1A1 (0.60) | ALDH1A1CA1HTTLMNACA2 | |
| SCHEMBL11033708 | 0.77 | ALDH1A1 (1.00) | ALDH1A1CA1HTTLMNACA2 | |
| SCHEMBL5114807 | 0.77 | ALDH1A1 (0.60) | ALDH1A1CA1HTTLMNACA2 | |
| SCHEMBL13715429 | 0.77 | ALDH1A1 (0.60) | ALDH1A1CA1HTTLMNACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793563-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20190169140-A1 | IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169140-A1 | IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | IDO1, IDO2, INMT | ALDH1A1 304/4885CA1 2399/4885HTT 1543/4885 |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | ALDH1A1 4414/4885CA1 4106/4885HTT 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.